close
  • Approved Use: Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen is not responsible for and does not endorse or control the content contained on this third-party website.

Continue

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen & Novartis are not responsible for and do not endorse or control the content contained on this third-party website.

Continue
  1. Access to americanmigrainefoundation.org is not intended to provide medical advice or a referral to a particular physician;
  2. Patients should discuss with their physician their experience with the patient’s medical condition and should then determine if the physician is qualified to perform the procedure;
  3. Patients should discuss the risks and benefits of any procedure with their physician;
  4. americanmigrainefoundation.org is an independent entity, and not affiliated with, or an agent of, Amgen Inc.
  5. Amgen Inc. has not entered into any agreement with any doctor affiliated with americanmigrainefoundation.org to render any treatment or care to any patient, and has not evaluated the credentials, experience or expertise of any physician affiliated with, or referred through, americanmigrainefoundation.org.
  6. AMGEN INC. MAKES NO EXPRESS, IMPLIED OR STATUTORY WARRANTIES OR REPRESENTATIONS (INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) AMERICANMIGRAINEFOUNDATION.ORG. TO THE MAXIMUM EXTENT PERMITTED BY LAW, AMGEN INC. AND ITS AFFILIATES ARE NOT RESPONSIBLE FOR AND EXPRESSLY DISCLAIM ALL LIABILITY, INCLUDING WITHOUT LIMITATION, FOR DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, AND SPECIAL OR OTHER DAMAGES ARISING FROM OR RELATED TO THE USE OF ANY SERVICES OFFERED BY AMERICANMIGRAINEFOUNDATION.ORG. BY ACCESSING AMERICANMIGRAINEFOUNDATION.ORG, YOU AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW THAT YOU WILL HOLD AMGEN INC. AND ITS AFFILIATES HARMLESS FROM ANY AND ALL CLAIMS ARISING FROM OR IN CONNECTION WITH ANY ACT OR OMISSION OF AMERICANMIGRAINEFOUNDATION.ORG.

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen Inc. is not responsible for and does not endorse or control the content contained on this third-party website.

Click “OK” to proceed or “CANCEL” to return to aimovig.com

By clicking “OK” below, you acknowledge that you have read and reviewed the information contained within the Notice of Third-Party Site at the bottom of the page.

OK CANCEL
Why Aimovig
SCROLL
Why Aimovig

Aimovig is...

Proven to help prevent monthly migraine days before they start—in some cases, it can cut that number in half or more.

Proven to help prevent monthly migraine days before they start—in some cases, it can cut that number in half or more.

The first preventive treatment designed to block the CGRP receptor, which may play a key role in migraine.

One dose, once a month is designed to keep working 24/7, to help reduce monthly migraine days. For some, it cuts the number by 50% or more.

In a clinical study, months 4-6. Aimovig is taken by injection.

The cost of Aimovig varies by person. We may be able to help you with financial support options, like the copay card for eligible commercially insured patients.

Ask your doctor if Aimovig is right for you

Whether you’re talking to a neurologist or your primary care doctor, this personalized guide can help you share the impact of migraine on your daily life and discuss if Aimovig is right for you.

Get the guide
Don't have a doctor? Here are some resources to help find one.
"

I can wake up on most days and pursue my daily life; before, for so long, I couldn't.”

Delora D.

AIM Network Member

Delora is an actual patient.
Individual results may vary.

"

With a reduction in monthly migraine days, I'm able to plan more of my everyday life than planning my down time.”

Lisa G.

AIM Network Member

Lisa is an actual patient.
Individual results may vary.

"

It just feels very good to not have to factor in migraine all the time in my life anymore.”

Dayna D.

AIM Network Member

Dayna is an actual patient.
Individual results may vary.

Frequently asked questions

  • What is Aimovig?
    Aimovig is a prescription medicine used to help prevent migraine in adults. Aimovig is the first and only FDA-approved treatment that blocks the CGRP receptor to help prevent migraine.
  • How do I pronounce Aimovig?

    Just three simple syllables:

    Aimovig

    AIM-oh-vig

    /‘eɪmoʊvɪg/

    erenumab-aooe

    eh-REN-yoo-mab

    /e’renju:mæb/

    listen Hear it
  • What are monthly migraine days?
    Monthly migraine days (MMD) are the number of calendar days per month that you had an onset, continuation, or recurrence of a migraine headache.
  • How do I know if I’m ready for Aimovig?
    Your doctor will determine if Aimovig is right for you. When you go to your appointment, it is helpful to be prepared with talking points to discuss. Our personalized discussion guide can help you talk with your doctor about how your migraine affects you.

Contact us here

1-833-AIMOVIG (1-833-246-6844)

8AM–9PM ET, Mon–Fri

+ +

Important Safety Information

Who should not use Aimovig®?
Do not use Aimovig if you are allergic to erenumab-aooe or any ingredients in

Who should not use Aimovig? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are allergic to rubber or latex, pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.

 
–

Important Safety Information

Who should not use Aimovig®? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are allergic to rubber or latex, pregnant or plan to become pregnant, breastfeeding or plan to breastfeed. Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements. What are possible side effects of Aimovig®? Aimovig® may cause serious side effects, including:
  • Allergic reactions. Allergic reactions, including rash or swelling can happen after receiving Aimovig®. This can happen within hours to days after using Aimovig®. Call your HCP or get emergency medical help right away if you have any of the following symptoms of an allergic reaction: swelling of the face, mouth, tongue or throat, or trouble breathing.
  • Constipation with serious complications. Severe constipation can happen after receiving Aimovig®. In some cases people have been hospitalized or needed surgery. Contact your HCP if you have severe constipation.
  • High blood pressure. High blood pressure or worsening of high blood pressure can happen after receiving Aimovig®. Contact your healthcare provider if you have an increase in blood pressure.
The most common side effects of Aimovig® are pain, redness, or swelling at the injection site and constipation. These are not all of the possible side effects of Aimovig®. Call your HCP for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Click here for the full Prescribing Information and Patient Product Information.

Approved Use

Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.
References: 1. Parsabiv® (etelcalcetide) prescribing information, Amgen. 2. Data on file, Amgen; [Summary of Clinical Efficacy; 2015]. 3. Alexander ST, et al. Mol Pharmacol. 2015;88:853-865. 4. Data on file, Amgen; [Report R20130052, 2014]. 5. Chen P, et al. CPT Pharmacometrics Syst Pharmacol. 2016;5:484-494. 6. Sensipar® (cinacalcet) prescribing information, Amgen. 7. Ma JN, et al. J Pharmacol Exp Ther. 2011;337:275-284.